These findings are consistent with those of previous studies describing overrepresentation of KRAS mutations and metabolic dysregulation in CMS3 CRC cases and are common features with gastric and pancreatic cancers [33, 48–50]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.